Leqvio Cost in Idaho 2026: Price, Insurance, Medicaid, and Compounded Options

What Is Leqvio and Why Does the Price Matter in Idaho?

Inclisiran, sold as Leqvio, is a small interfering RNA (siRNA) that silences PCSK9 production in hepatocytes, dropping LDL-C by roughly half with only two injections per year after the initial loading phase [1]. The drug was FDA-approved on December 22, 2021 for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering on top of maximally tolerated statin therapy [2].

Idaho has roughly 1.9 million residents, a rural geography that limits in-office cardiology access, and a Medicaid program that has not yet added Leqvio to its preferred drug list [3]. That combination means price is a genuine barrier. A patient who cannot manage insurance or manufacturer programs could face a $6,480 annual out-of-pocket bill at list price, which is why understanding every access pathway matters before the first injection is ordered.

The twice-yearly dosing schedule is both a clinical advantage and a coverage complication. Because Leqvio is administered by a healthcare provider and billed under the medical benefit in many plans, prior-authorization rules differ from the pharmacy benefit workflows that patients and prescribers are used to with statins or even oral PCSK9 agents [2].

ORION Trials: What the Evidence Says About Inclisiran's Efficacy

Inclisiran's approval rests primarily on ORION-10 and ORION-11, both published in the New England Journal of Medicine in March 2020 [1]. ORION-10 enrolled 1,561 patients with ASCVD on maximally tolerated statins and demonstrated a 52.3% placebo-corrected reduction in LDL-C at day 510 (P<0.001) [1]. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents and showed a 49.9% placebo-corrected LDL-C reduction at day 510 (P<0.001) [1].

Adverse event rates were low. Injection-site reactions occurred in 2.6% of inclisiran-treated patients versus 0.9% in the placebo arm across pooled ORION data, and no serious hepatic or renal safety signals emerged [1]. The FDA label confirms this profile [2].

The ORION-4 outcomes trial (N=approximately 15,000; ClinicalTrials.gov NCT03705234) is ongoing and designed to determine whether those LDL reductions translate into reduced major adverse cardiovascular events. Results are expected around 2026 [4]. Prescribers citing only the surrogate LDL endpoint should communicate that uncertainty to patients, as the American College of Cardiology's 2022 Expert Consensus Decision Pathway advises [5].

The ACC guidance states: "For patients with clinical ASCVD at very high risk, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, PCSK9 inhibitor therapy should be considered" [5]. Inclisiran fits within that framework as a twice-yearly alternative to the biweekly or monthly injectable PCSK9 antibodies evolocumab (Repatha) and alirocumab (Praluent).

Leqvio List Price in Idaho in 2026

The Novartis wholesale acquisition cost (WAC) for Leqvio is approximately $3,250 per single-dose prefilled syringe (284 mg/1.5 mL). Because patients receive two injections in year one (loading doses at day 1 and day 90) and two injections in subsequent years, the annualized WAC works out to roughly $6,500 per year, or about $540 per month when expressed as a monthly equivalent [6].

Cash-pay patients in Idaho retail pharmacies should expect to pay close to that WAC figure. GoodRx and similar discount programs offer minimal savings on Leqvio because the drug's complex billing pathway through the medical benefit makes standard pharmacy coupon aggregators less applicable than they are for oral medications.

Idaho has no state-level drug pricing transparency law that caps WAC-to-patient spreads, so the $540/month figure is the practical floor for uninsured, cash-pay patients who seek the brand product [3]. Patients with Medicare Part B may face a 20% coinsurance on the Medicare-allowed amount, which varies by contractor. In 2024, the Medicare Part B payment for inclisiran was set through the ASP-plus-6% methodology; that figure is updated quarterly by CMS [7].

Idaho Medicaid Coverage for Leqvio

Idaho Medicaid does not cover Leqvio as of July 2025 [3]. The Idaho Division of Medicaid uses a Preferred Drug List (PDL) administered through a pharmacy benefits manager, and inclisiran does not appear on that PDL. Non-preferred PCSK9 agents may be accessible through a prior authorization exception, but approval rates for non-PDL specialty biologics in Idaho Medicaid are low without documented statin intolerance and a failure of at least one preferred formulary agent.

Medicaid members who believe they have a medically necessary claim can request a prior authorization or appeal a denial. The Idaho Department of Health and Welfare outlines that process under 42 CFR §431.200 [8]. Patients with HeFH who meet medical necessity criteria have the strongest argument, given the FDA's labeled indication [2].

For Medicaid-eligible Idaho patients who cannot get coverage, the Novartis patient assistance program (see the section below) may be an option if income thresholds are met. Medicaid enrollment does not automatically disqualify a patient from manufacturer assistance, but program rules change annually.

Commercial Insurance Coverage in Idaho

Most major commercial insurers operating in Idaho, including Blue Cross of Idaho, SelectHealth, and PacificSource, list Leqvio on their specialty tier with a prior authorization requirement [9]. Typical prior-authorization criteria mirror the FDA label: diagnosed ASCVD or HeFH, LDL-C at or above 70 mg/dL (or 100 mg/dL for primary prevention HeFH), documented use of maximally tolerated statin therapy, and in many cases a trial of ezetimibe [9].

Prior authorization approvals generally run for 12 months and require renewal with updated lipid panel results. The prescriber's office carries most of the administrative burden for PA submission. Patients using telehealth prescribers in Idaho should confirm the telehealth platform has a clinical staff member who can handle PA paperwork, because the injection itself still must occur in a medical setting.

Once approved, the actual out-of-pocket cost depends on plan design. Patients on high-deductible health plans may owe the full allowed amount until the deductible is met. After the deductible, specialty-tier cost-sharing commonly runs 20% to 33% coinsurance, putting per-injection costs anywhere from $300 to $700 for patients without additional assistance [9].

Novartis Savings Card and Patient Assistance in Idaho

The Novartis Leqvio savings card is available to commercially insured patients who are not enrolled in a federal or state government health program (meaning Medicare, Medicaid, TRICARE, and CHIP patients are excluded). Eligible patients may pay as little as $0 per injection, up to a per-year cap that Novartis sets annually [6].

To enroll, the prescriber's office typically activates the savings card through the Novartis hub, known as the Leqvio One Source program. The hub also handles benefits verification, prior authorization support, and scheduling of injections at participating clinical sites.

Novartis also operates the Novartis Patient Assistance Foundation (NPAF), which provides free medication to uninsured or underinsured patients whose household income falls below approximately 400% of the federal poverty level [6]. Idaho patients without commercial insurance should contact NPAF directly at 1-800-277-2254 or through the Leqvio One Source portal.

The HealthRX Access Decision Framework for Idaho Leqvio Patients:

1. Commercially insured: Activate the Novartis savings card through your prescriber's office before the first injection. Target $0 copay.
2. Idaho Medicaid: Submit a prior-authorization exception request with documentation of HeFH or very-high-risk ASCVD and statin intolerance. If denied, escalate to the NPAF or ask about compounded inclisiran.
3. Medicare Part B: No savings card eligibility. Explore the Medicare Extra Help program (Low Income Subsidy) if income-qualified. Ask your cardiologist whether alirocumab or evolocumab, which are pharmacy-benefit drugs, would cost less under your plan.
4. Uninsured / cash-pay: Compare brand cost against 503A-compounded inclisiran after physician assessment of candidacy.

Compounded Inclisiran in Idaho: Legality and Practicalities

Compounded inclisiran is legal in Idaho when prepared by a licensed 503A pharmacy operating under a valid patient-specific prescription [10]. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare copies of FDA-approved drugs for individual patients, provided there is a valid prescriber-patient relationship and the compound is not on the FDA's list of drugs withdrawn for safety reasons [10].

Inclisiran is not on that withdrawn list, and the FDA has not issued a specific enforcement policy restricting 503A compounding of inclisiran as of mid-2025 [10]. Some 503B outsourcing facilities (which serve healthcare institutions rather than individual patients) have added inclisiran to their menu as well, though the regulatory picture for 503B compounders is subject to change as the brand product's market exclusivity matures.

Cost for compounded inclisiran varies by pharmacy, concentration, and formulation. Several 503A pharmacies working with telehealth platforms in the western United States quote prices well below brand WAC. For Idaho patients, the effective cost could approach $0 per month when the compounded version is included in a bundled telehealth membership, or it may be quoted as a per-vial cash price ranging from $150 to $400 per injection, depending on the pharmacy [11].

Patients and prescribers considering compounded inclisiran should verify three things: the pharmacy holds an active 503A license in Idaho (confirmed through the Idaho Board of Pharmacy), the compounding meets USP standards for sterile injectables, and the prescribing physician has documented the clinical rationale for choosing the compounded version over the brand [10]. The American Society of Health-System Pharmacists recommends sterility verification for all compounded injectables [12].

Quality data on compounded inclisiran's bioequivalence to Leqvio are not publicly available in peer-reviewed literature as of 2025. Patients should weigh that uncertainty against the cost difference, ideally in a shared decision-making conversation with their prescriber.

Telehealth Prescribing of Leqvio in Idaho

Telehealth prescribing of Leqvio is legal in Idaho [3]. Idaho participates in the Interstate Medical Licensure Compact, which allows out-of-state physicians to obtain expedited licensure to treat Idaho patients [13]. Several national telehealth platforms that specialize in preventive cardiology and metabolic health now offer inclisiran prescribing services for Idaho residents.

The prescription is only half the process. Because inclisiran is a subcutaneous injection that must be administered by a healthcare provider, the patient still needs an in-person clinical encounter for each dose. Telehealth platforms typically coordinate with local primary care offices, urgent care clinics, or infusion centers to handle the administration piece. Patients in rural Idaho counties, where the nearest cardiologist may be 90 miles away, should confirm that a local administration site is available before starting therapy.

Telehealth-prescribed inclisiran, including the compounded version, follows the same prior-authorization requirements as in-person prescriptions when billed through commercial insurance. The telehealth prescriber's National Provider Identifier (NPI) must be enrolled with the patient's insurer [13].

How Inclisiran Compares to Other PCSK9 Options in Idaho

Three PCSK9-targeting drugs are available in the United States: evolocumab (Repatha, Amgen), alirocumab (Praluent, Regeneron/Sanofi), and inclisiran (Leqvio, Novartis). All three reduce LDL-C by 50% to 60% in statin-treated patients with ASCVD, and evolocumab and alirocumab have published cardiovascular outcomes trial data [14][15].

The FOURIER trial (N=27,564) showed evolocumab reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.79 to 0.92; P<0.001) after a median 2.2 years [14]. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% relative to placebo in post-ACS patients (P<0.001) [15].

Inclisiran lacks a published MACE outcomes trial as of 2025, which is the single most important clinical distinction. From a cost standpoint, Repatha and Praluent list at similar annual WAC figures to Leqvio, but both are dispensed through the pharmacy benefit, making GoodRx and manufacturer copay cards more straightforward to apply for many Idaho patients [6][16].

The practical summary for most Idaho prescribers: if a patient is commercially insured and eligible for the Novartis savings card, Leqvio's twice-yearly administration may be a convenience win. For Medicare patients or those with insurance that covers pharmacy-benefit drugs more favorably, evolocumab or alirocumab may cost less out of pocket.

What to Bring to Your First Leqvio Appointment in Idaho

Preparing for the first inclisiran injection can prevent billing surprises. Patients should bring insurance cards for both medical and pharmacy benefits, because the billing pathway (medical versus pharmacy benefit) affects how the savings card is applied. A recent lipid panel, ideally within the past 90 days, is typically required for prior-authorization submission [9].

The FDA label specifies that LDL-C should be measured before initiation and at 3 months after the first dose to confirm response [2]. A 3-month LDL-C below the patient's target (generally <70 mg/dL for ASCVD or <100 mg/dL for HeFH primary prevention) suggests the drug is working. If LDL-C does not fall by at least 30%, the prescriber should assess adherence to concurrent statin therapy before assuming non-response to inclisiran [2].

Injection-site reactions are the most common adverse effect reported in ORION trials, occurring in roughly 2.6% of participants [1]. These are generally mild and self-limiting. Serious hypersensitivity reactions are rare but documented in post-marketing reports; patients should wait 30 minutes at the clinical site after the first injection [2].

Monitoring LDL-C After Inclisiran in Idaho

LDL-C monitoring after inclisiran follows the same general framework endorsed by the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol [17]. The guideline recommends a fasting lipid panel 4 to 12 weeks after starting or adjusting any LDL-lowering therapy and every 3 to 12 months thereafter [17].

For inclisiran specifically, the drug's LDL-lowering effect peaks at roughly 30 days post-injection and remains relatively stable through the 6-month dosing interval, which means a single annual lipid check (timed 30 to 60 days after an injection) is often sufficient for patients who have reached their LDL-C target [1][2]. Idaho patients using a rural telehealth prescriber can have their lipid panel drawn at any local LabCorp or Quest Diagnostics draw station and upload results through the telehealth portal.

The Endocrine Society's 2020 Clinical Practice Guideline on dyslipidemia management recommends confirming a treatment response with at least two LDL-C measurements before concluding a patient is a non-responder to any PCSK9 inhibitor [18]. That same guideline notes that siRNA-based agents like inclisiran may show slightly delayed nadir LDL-C compared to monoclonal antibody PCSK9 inhibitors [18].

Specific Steps to Access Leqvio in Idaho Right Now

Patients ready to start the access process can take these steps in order. First, have the prescribing provider check your insurance formulary status through the Leqvio One Source hub (1-833-LEQVIO1). Second, if commercially insured, enroll in the Novartis savings card before the injection is scheduled. Third, if insured through Idaho Medicaid or Medicare, ask the prescriber's office to document HeFH or very-high-risk ASCVD criteria for a prior-authorization exception. Fourth, if cost remains a barrier after exhausting manufacturer programs, ask the prescriber whether compounded inclisiran from a licensed 503A Idaho pharmacy is appropriate for your clinical situation.

The ACC's 2022 Expert Consensus Decision Pathway for Non-Statin Therapies states: "Cost and patient access are key determinants of PCSK9 inhibitor utilization, and clinicians should proactively discuss financial assistance programs at the time of prescribing" [5]. Idaho patients deserve that conversation before, not after, the first injection is scheduled.